Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

Is Illumina a victim of its own success? What makes the FDA change its mind? And how will petrodollars change biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treatment, the latest in cancer research, and a well-funded new player in biotech venture capital.

Read the rest…

Click here to view original post